HOTH News and Press, Hoth Therapeutics Inc.

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PR Newswire AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK , March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDA...

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES PR Newswire CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW YORK , ...

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases PR Newswire Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio NEW YORK , Feb. ...

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model PR Newswire In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administr...

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PR Newswire NEW YORK , Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),  a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer pa...

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients PR Newswire Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; ...

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position PR Newswire Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's L...

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation PR Newswire Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of si...

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PR Newswire NEW YORK , Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics  (NASDAQ: HOTH) , a clinical-stage biopharmaceutical company developing inno...

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program PR Newswire NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) , a patient-fo...